Topical dexamethasone–cyclodextrin nanoparticle eye drops for non‐infectious Uveitic macular oedema and vitritis – a pilot study

Abstract

ABSTRACT.Purpose: To evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis. Methods: In a prospective pilot study, DexNP drops were administered four times a day for 4 weeks followed by drops tapering over a period of another 4 weeks. Follow-up time was 12 weeks. Results: Five eyes with macular oedema and three eyes with vitritis were included in the study. Best corrected visual acuity (BCVA) significantly improved from a median of 0.2 logMAR to a median of 0.15 logMAR at 4 weeks' time (p < 0.05). Median BCVA was 0.175 logMAR and 0.2 logMAR, at week 8 and 12, respectively (p > 0.05). Macular oedema significantly improved at all timepoints as compared to baseline (p < 0.05) and resolved in all eyes during followup. One eye had macular oedema relapse at week 12. Vitritis improved in all eyes and resolved completely in two eyes. One eye had intraocular pressure (IOP) elevation which was well controlled with topical antihypertensive treatment, and one eye had cataract progression. Conclusion: This short pilot study demonstrates favourable effect of 1.5% DexNP eye drops on eyes with non-infectious uveitic macular oedema and vitritis. Further comparative long-term studies are warranted to assess this effect.

Treatment of non‐infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ‐cyclodextrin nanoparticle eye drops

“…Our results agreed with the previous studies that using 1.5% DexNP in inflammatory ocular conditions (Krag & Hessellund ; Shulman et al. ). Use of 1.5% DexNP eye drops for the treatment of anterior and posterior scleritis and Vogt‐Koyanagi‐Harada disease‐related papillitis has not been previously reported.…”

Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review

“…Corticosteroids are used extensively in treatment of ocular inflammation. Topical treatment is generally accepted not to affect posterior uveitis, though it may decrease anterior vitritis and cystoid macular oedema . Indications for systemic corticosteroid include vision‐threatening lesions, serous detachments and severe vitritis .…”

“…Topical treatment is generally accepted not to affect posterior uveitis, though it may decrease anterior vitritis and cystoid macular oedema. 67 Indications for systemic corticosteroid include vision-threatening lesions, serous detachments and severe vitritis. 10 Use in infectious uveitis generally mandates concurrent antimicrobial cover.…”

Preliminary study of a controllable device for subtenon drug infusion in a rabbit model

“…; Shulman et al. ). Intravenous administration can deliver drugs to intraocular tissues, but high doses are associated with systemic toxicities (Hughes et al.…”